

Hall: Main

16:00 - 17:00

Session I

Cardiology Fellows of tomorrow-

Cardiorisk decision making Case discussion

Moderator

EISayed Farag	
---------------	--

16:00 - 16:15	Case 1: Hypertension
16:15 - 16:20	Discussion
16:20 - 16:35	Case2: Dyslipidaemia
16:35 - 16:40	Discussion
16:40 - 16:55	Case3: Diabetes
16:55 - 17:00	Discussion

Hall: Main

17:05 - 18:05

Session II

Lipidology 1

Recent advances in lipid management

Moderator

Atef Elbahry	
--------------	--

- | | |
|---------------|---|
| 17:05 - 17:20 | Which Guidelines of lipid management , we should follow ? |
| 17:20 - 17:25 | Discussion |
| 17:25 - 17:40 | PCSK9 INHIBITORS : Their positions in CV risk Reduction |
| 17:40 - 17:45 | Discussion |
| 17:45 - 18:00 | EVALUATION & TREATMENT OF HYPERTRIGLYCERDEMIA |
| 18:00 - 18:05 | Discussion |

Hall: Main

18:10 - 19:10

Session III

DM 1

Diabetes and the heart

Chairperson

Osama Sanad	
-------------	--

Moderator

Sameh Salama	
--------------	--

18:10 - 18:25 How can we read the latest CV safety trials of anti-diabetic treatment

18:25 - 18:30 Discussion

18:30 - 18:45 New AHA/ADA guidelines for CV prevention in type 2 DM

18:45 - 18:50 Discussion

18:50 - 19:05 Insulin-Statin- PCSK 9 links points to new treatment horizon

19:05 - 19:10 Discussion

Hall: Main

19:30 - 20:30

Session IV

HTN 1

High risk hypertension scenarios

Chairperson

Ihab Attia	Nabil Farag
------------	-------------

Moderator

Mohamed Abdelghany	Osama Sanad
--------------------	-------------

19:30 - 19:45	Management of elderly hypertensives: an everlasting challenge
19:45 - 19:50	Discussion
19:50 - 20:05	Acute Severe Hypertension in neurological patient. What to do
20:05 - 20:10	Discussion
20:10 - 20:25	Resistant Hypertension : Approach from Guidelines
20:25 - 20:30	Discussion

Hall: Main

20:35 - 21:35

Session V

Imaging

Vascular imaging

Chairperson

Abdelrahman Sharaf	Azza Farag
Islam Shawky	Mohamed Ayman

Moderator

Iman Elsharkawy	
-----------------	--

20:35 - 20:45	Case1
20:45 - 20:55	Case2
20:55 - 21:05	Case3
21:05 - 21:15	Case4
21:15 - 21:25	Talk5
21:25 - 21:35	Talk6

Wednesday, Nov 23, 2016

Hall: Main

21:40 - 22:20

Sanofi Symposium

Hall: Main

16:00 - 17:00

Session VI

Lipid 2

Lipid disorders you need to know

Chairperson

Ahmed Shawky	
--------------	--

Moderator

Atef Elbahry	
--------------	--

16:00 - 16:15	CHYLOMICRONE SYNDROME
16:15 - 16:20	Discussion
16:20 - 16:35	POLYGENIC HYPERCHOLESTEROLEMIA
16:35 - 16:40	Discussion
16:40 - 16:55	FAMILIAL Hypercholesterolaemia : Scope of the problem
16:55 - 17:00	Discussion

Hall: Main

17:05 - 18:05

Session VII

HTN 2

Hypertension : Questions to be Answered

17:05 - 17:20

The lower the better dilemma and Hypertension guidelines

17:20 - 17:25

Discussion

17:25 - 17:40

Visit-to-Visit Blood Pressure Variability --An Insight Into the Mechanisms and prognosis

17:40 - 17:45

Discussion

17:45 - 18:00

What Is the Optimal Strategy to Manage Hypertension During Pregnancy?

18:00 - 18:05

Discussion

Thursday, Nov 24, 2016

Hall: Main

18:10 - 18:40

Astrazenca Symposium-HOPE-3

Hall: Main

18:45 - 19:45

Session VIII

Quad 1

Quad of the trials 1

18:45 - 18:57	PARADIGM-HF
18:57 - 19:00	Discussion
19:00 - 19:12	ODYSSEY HeFH long term data
19:12 - 19:15	Discussion
19:15 - 19:27	ARISTOTLE Trial
19:27 - 19:30	Discussion
19:30 - 19:42	TECOS Cv safetytrial
19:42 - 19:45	Discussion

Hall: Main

20:00 - 20:30

Servier Symposium

Hall: Main

20:35 - 21:35

Session IX

DM 2

Cardio-Diabetology :The huge overlap

Moderator

Sameh Salama	
--------------	--

- | | |
|---------------|---|
| 20:35 - 20:50 | Treatment of heart failure in the diabetics does it differ? |
| 20:50 - 20:55 | Discussion |
| 20:55 - 21:10 | Hypoglycemia and CV disease: causation or Association? |
| 21:10 - 21:15 | Discussion |
| 21:15 - 21:30 | Coud New diabetic lowering agents improve CV outcomes? |
| 21:30 - 21:35 | Discussion |

Hall: Main

21:40 - 22:20

Industry Symposium

Hall: Main

16:00 - 17:00

Session X

Lipid 3

Molecular biology and pharmacogenomics

Moderator

Atef Elbahry	
--------------	--

16:00 - 16:15	STATIN METABOLIZER SLOC1B1: Which genotype are you?
16:15 - 16:20	Discussion
16:20 - 16:35	MUTATION of LDL RECEPTORS GENE & INCREASED RISK OF CHD
16:35 - 16:40	Discussion
16:40 - 16:55	Pick C1-like protein variants & premature atherosclerosis
16:55 - 17:00	Discussion

Hall: Main

17:05 - 18:05

Sessio XI

Quad 3

QUAD of the trials 3

17:05 - 17:17	SPRINT
17:17 - 17:20	Discussion
17:20 - 17:32	ON TARGET
17:32 - 17:35	Discussion
17:35 - 17:47	DAPT
17:47 - 17:50	Discussion
17:50 - 18:02	LEADER
18:02 - 18:05	Discussion

Hall: Main

18:10 - 19:10

Session XII

Cath 1

Life in a box

Tools in the cathlab: Anatomy/physiology and vascular biology

Moderator

Ahmed khashaba	Hazem khamis
----------------	--------------

Panelist

Hany Ragy	Mohamed Sobhy
Nabil Farag	

Hall: Main

19:30 - 20:00

Industry Symposium

Hall: Main

20:05 - 21:35

Session XIII

Thrombo 1

Antithrombotic in special populations with ACS

Coordinator

Amr Kamal	
-----------	--

20:05 - 20:40	Antithrombotic treatment of ACS patients with diabetes mellitus
20:20 - 20:25	Discussion
20:25 - 20:40	Antithrombotic treatment of ACS patients with diabetes mellitus
20:40 - 20:45	Discussion
20:45 - 21:10	Optimal antithrombotic treatment of medically managed ACS patients
21:10 - 21:15	Discussion
21:15 - 21:30	Antithrombotic treatment of elderly patients
21:30 - 21:35	Discussion

Hall: Main

21:40 - 22:30

Session XIII

Quad 2

Quad of the trial 2

Moderator

Sameh Salama	
--------------	--

21:52 - 22:00 Discussion
22:00 - 22:12 SHIFT trial and a new heart failure prognostic model

22:12 - 22:15 Discussion
22:15 - 22:27 IMPROVE- IT

22:27 - 22:30 Discussion
22:30 - 21:52 Lessons derived from OSLER program

Hall: Main

21:50 - 23:30

Hot Debates in Antiplatelet Treatment

Moderator

Amr Kamal	
-----------	--

22:30 - 22:42

Debate 1: Pretreatment in ACS

Pre-treatment with P2Y12 inhibitors in NSTEMI/ACS

Pro:

22:42 - 22:54

Cons:

22:54 - 23:00

Rebuttal & Discussion

23:00 - 23:12

Debate 2: Management of low risk ACS patient

Troponin Negative low risk ACS patients undergoing Ad Hoc PCI
(Ticagrelor is better)

Pro:

23:12 - 23:24

Cons:

23:24 - 23:30

Rebuttal & Discussion